Zenas BioPharma (ZBIO) & Its Peers Head to Head Survey

Zenas BioPharma (NASDAQ:ZBIO) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Zenas BioPharma to similar businesses based on the strength of its profitability, earnings, institutional ownership, risk, dividends, valuation and analyst recommendations.

Valuation and Earnings

This table compares Zenas BioPharma and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Zenas BioPharma	$10.00 million	-$377.74 million	-3.14
Zenas BioPharma Competitors	$705.29 million	$10.71 million	-15.00

Zenas BioPharma’s rivals have higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current ratings and target prices for Zenas BioPharma and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zenas BioPharma	1	2	6	0	2.56
Zenas BioPharma Competitors	9829	15119	45431	1586	2.54

Zenas BioPharma currently has a consensus target price of $46.71, suggesting a potential upside of 65.30%. As a group, “Biotechnology” companies have a potential upside of 102.69%. Given Zenas BioPharma’s rivals higher possible upside, analysts plainly believe Zenas BioPharma has less favorable growth aspects than its rivals.

Institutional and Insider Ownership

47.9% of shares of all “Biotechnology” companies are held by institutional investors. 22.0% of Zenas BioPharma shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Zenas BioPharma has a beta of -0.88, indicating that its stock price is 188% less volatile than the S&P 500. Comparatively, Zenas BioPharma’s rivals have a beta of 1.15, indicating that their average stock price is 15% more volatile than the S&P 500.

Profitability

This table compares Zenas BioPharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zenas BioPharma	N/A	-136.40%	-61.40%
Zenas BioPharma Competitors	-12,357.18%	-197.96%	-30.56%

Summary

Zenas BioPharma rivals beat Zenas BioPharma on 7 of the 12 factors compared.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.